Inscripta™ says proprietary CRISPR enzyme achieved wide adoption during first year on the market

January 1, 2019 |

In Colorado, Inscripta™, a leading gene-editing technology company, announced that MAD7, its proprietary CRISPR enzyme, has achieved wide adoption by academic, commercial, and government researchers in its first year of availability. MAD7 was recently recognized by the Scientist magazine as one of the “Top 10 Innovations of 2018.”

To build on the progress that Inscripta has had over the past 12 months and to speed the development and commercialization of its cutting-edge, gene-editing tools, the company’s existing investors have agreed to contribute an additional $30 million in funding, bringing the 2018 fundraising total to $85.5 million.

Print Friendly, PDF & Email

Tags: , ,

Category: Producer News

Thank you for visting the Digest.